Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results

被引：4

作者：

DeAngelo, Daniel J. ^{[1
]}

Mauro, Michael J. ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Cortes, Jorge ^{[4
]}

Rea, Delphine ^{[5
]}

Hughes, Timothy P. ^{[6
,7
]}

Minami, Hironobu ^{[8
]}

Breccia, Massimo ^{[9
]}

Talpaz, Moshe ^{[10
]}

Hochhaus, Andreas ^{[11
]}

Goh, Yeow Tee ^{[12
]}

Le Coutre, Philipp D. ^{[13
]}

Sondhi, Manu ^{[14
]}

Mishra, Kaushal ^{[14
]}

Hourcade-Potelleret, Florence ^{[15
]}

Vanasse, Gary ^{[15
]}

Aimone, Paola ^{[15
]}

Lang, Fabian ^{[16
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Leukemia Res Inst, Seoul, South Korea

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Hop St Louis, Paris, France

[6] SA Pathol, Adelaide, SA, Australia

[7] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[8] Kobe Univ Hosp, Kobe, Hyogo, Japan

[9] Univ Roma La Sapienza, Rome, Italy

[10] Univ Michigan, Ann Arbor, MI 48109 USA

[11] Univ Klinikum Jena, Abt Hamatol Onkol, Jena, Germany

[12] Singapore Gen Hosp, Singapore, Singapore

[13] Charite Univ Med Berlin, Berlin, Germany

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Novartis Pharma AG, Basel, Switzerland

[16] Goethe Univ Frankfurt Main, Frankfurt, Germany

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷

关键词：

asciminib; tyrosine kinase inhibitor; clinical trial; CML; chronic myelogenous leukemia;

D O I：

10.1016/j.clml.2019.07.236

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-102

引用

页码：S290 / S291

页数：3

共 50 条

[41] Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial [J].

Gore, Lia ;

Kearns, Pamela R. ;

de Martino Lee, Maria Lucia ;

De Souza, Carmino Antonio ;

Bertrand, Yves ;

Hijiya, Nobuko ;

Stork, Linda C. ;

Chung, Nack-Gyun ;

Cardos, Rocio Cardenas ;

Saikia, Tapan ;

Fagioli, Franca ;

Seo, Jong Jin ;

Landman-Parker, Judith ;

Lancaster, Donna ;

Place, Andrew E. ;

Rabin, Karen R. ;

Sacchi, Mariana ;

Swanink, Rene ;

Zwaan, C. Michel .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (13) :1330-+

[42] Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure [J].

Gomez-Almaguer, David ;

Saldana-Vazquez, Roxana ;

Tarin-Arzaga, Luz ;

Angel Herrera-Rojas, Miguel ;

Vazquez-Mellado de Larracoechea, Alberto ;

Graciela Cantu-Rodriguez, Olga ;

Homero Gutierrez-Aguirre, Cesar ;

Carlos Jaime-Perez, Jose .

Hematology, 2016, 21 (07) :411-414

[43] Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study [J].

Cortes, Jorge ;

Lynn Huynh ;

Mendelson, Estella ;

Brandt, Patricia ;

Dalal, Darshan ;

DerSarkissian, Maral ;

Cortina, Diego ;

Narkhede, Sahil ;

Duh, Mei Sheng .

LEUKEMIA & LYMPHOMA, 2020, 61 (01) :98-107

[44] Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study) [J].

Roy, Lydia ;

Chomel, Jean-Claude ;

Guilhot, Joelle ;

Guerci-Bresler, Agnes ;

Escoffre-Barbe, Martine ;

Giraudier, Stephane ;

Charbonnier, Aude ;

Dubruille, Viviane ;

Huguet, Francoise ;

Johnson-Ansah, Hyacinthe ;

Lenain, Pascal ;

Ame, Shanti ;

Etienne, Gabriel ;

Nicolini, Franck E. ;

Rea, Delphine ;

Cony-Makhoul, Pascale ;

Courby, Stephane ;

Ianotto, Jean-Christophe ;

Legros, Laurence ;

Machet, Antoine ;

Coiteux, Valerie ;

Hermet, Eric ;

Cayssials, Emilie ;

Bouchet, Stephane ;

Mahon, Francois-Xavier ;

Rousselot, Philippe ;

Guilhot, Francois .

BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (02) :175-186

[45] The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group [J].

Iriyama, Noriyoshi ;

Ohashi, Kazuteru ;

Hashino, Satoshi ;

Kimura, Shinya ;

Nakaseko, Chiaki ;

Takano, Hina ;

Hino, Masayuki ;

Uchiyama, Michihiro ;

Morita, Satoshi ;

Sakamoto, Junichi ;

Sakamaki, Hisashi ;

Inokuchi, Koiti .

INTERNAL MEDICINE, 2018, 57 (01) :17-23

[46] Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib [J].

Kim, T. D. ;

Rea, D. ;

Schwarz, M. ;

Grille, P. ;

Nicolini, F. E. ;

Rosti, G. ;

Levato, L. ;

Giles, F. J. ;

Dombret, H. ;

Mirault, T. ;

Labussiere, H. ;

Lindhorst, R. ;

Haverkamp, W. ;

Buschmann, I. ;

Doerken, B. ;

le Coutre, P. D. .

LEUKEMIA, 2013, 27 (06) :1316-1321

[47] Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML) [J].

Gambacorti-Passerini, Carlo ;

Abboud, Camille ;

Gjertsen, Bjorn Tore ;

Bruemmendorf, Tim ;

Smith, B. Douglas ;

Giraldo-Castellano, Pilar ;

Stromberg, Ulla ;

Saussele, Susanne ;

Bardy-Bouxin, Nathalie ;

Viqueira, Andrea ;

Leip, Eric ;

Leone, Jocelyn ;

Rosti, Gianantonio ;

Watts, Justin ;

Giles, Frank ;

Hochhaus, Andreas .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S290-S290

[48] Nilotinib vs dasatinib in achieving MR 4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study [J].

Matsumura, Itaru ;

Ohtake, Shigeki ;

Atsuta, Yoshiko ;

Kurata, Mio ;

Minami, Yosuke ;

Takahashi, Naoto ;

Nakaseko, Chiaki ;

Iriyama, Noriyoshi ;

Fujimaki, Katsumichi ;

Kakihana, Kazuhiko ;

Ogasawara, Yoji ;

Ono, Takaaki ;

Okada, Masaya ;

Tauchi, Tetsuzo ;

Miyamoto, Toshihiro ;

Ohnishi, Kazunori ;

Sakaida, Emiko ;

Fujisawa, Shin ;

Kobayashi, Yukio ;

Asou, Norio ;

Naoe, Tomoki ;

Kiyoi, Hitoshi ;

Miyazaki, Yasushi ;

Japan Adult Leukemia Study Group, for the Japan Adult Leukemia Study Group .

BLOOD ADVANCES, 2024, 8 (20) :5237-5247

[49] Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase - inhibitors a single center experience [J].

Ribeiro, Beatriz Felicio ;

Miranda, Eliana C. M. ;

de Albuquerque, Dulcineia Martins ;

Delamain, Marcia T. ;

Oliveira-Duarte, Gislaine ;

Almeida, Maria Helena ;

Vergilio, Bruna ;

Da Silveira, Rosana Antunes ;

Oliveira-Duarte, Vagner ;

Lorand-Metze, Irene ;

De Souza, Carmino A. ;

Pagnano, Katia B. B. .

CLINICS, 2015, 70 (08) :550-555

[50] Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment [J].

Levy, Moshe ;

Andorsky, David ;

Issa, Ghayas ;

Broun, Edward ;

Essell, James ;

Abboud, Camille ;

Damon, Andrea ;

Starinsky, Amy ;

Sadek, Islam ;

Parveen, Naseema ;

Mauro, Michael ;

Deininger, Michael .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S367-S367

← 1 2 3 4 5 →